Last reviewed · How we verify

Suzetrigine (SUZ) — Competitive Intelligence Brief

Suzetrigine (SUZ) (Suzetrigine (SUZ)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective sodium channel inhibitor. Area: Pain management / Neurology.

marketed Selective sodium channel inhibitor Voltage-gated sodium channels (Nav) Pain management / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Suzetrigine (SUZ) (Suzetrigine (SUZ)) — Vertex Pharmaceuticals Incorporated. Suzetrigine is a selective sodium channel inhibitor that reduces neuronal excitability by blocking voltage-gated sodium channels.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Suzetrigine (SUZ) TARGET Suzetrigine (SUZ) Vertex Pharmaceuticals Incorporated marketed Selective sodium channel inhibitor Voltage-gated sodium channels (Nav)
DS-5565 DS-5565 Daiichi Sankyo Co., Ltd. phase 3 Selective sodium channel inhibitor Voltage-gated sodium channels (Nav)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective sodium channel inhibitor class)

  1. Daiichi Sankyo Co., Ltd. · 1 drug in this class
  2. Vertex Pharmaceuticals Incorporated · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Suzetrigine (SUZ) — Competitive Intelligence Brief. https://druglandscape.com/ci/suzetrigine-suz. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: